Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF) (NCT05571059)
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Determine the Safety and Efficacy of Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
🩺 Plain-English Summary (8th-Grade Level)
Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.
Who can join: Review the eligibility criteria below.
Location: Biosolutions Clinical Research — La Mesa, California
Age range: 40 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (19 Sites)
- Biosolutions Clinical Research — La Mesa, California
- University of California San Francisco — San Francisco, California
- Mayo Clinic Jacksonville — Jacksonville, Florida
- Miami VA Health System — Miami, Florida
- Northwestern Medicine — Chicago, Illinois
- Indiana University Health — Indianapolis, Indiana
- University of Kansas — Kansas City, Kansas
- University of Louisville — Louisville, Kentucky
- Beaumont Hospital, Royal Oak — Royal Oak, Michigan
- Icahn School of Medicine at Mount Sinai — New York, New York
- University of Rochester — Rochester, New York
- UNC Chapel Hill — Chapel Hill, North Carolina
- Bend Memorial Hospital — Bend, Oregon
- Temple University Hospital — Philadelphia, Pennsylvania
- Avera Research Institute — Sioux Falls, South Dakota
- Pulmonary & Sleep Specialists — Dickson, Tennessee
- Baylor University Medical Center — Dallas, Texas
- Premier Pulmonary Critical Care and Sleep Medicine — Denison, Texas
- UW Health University Hospital — Madison, Wisconsin
📞 Contact the Study Coordinator
Phone: (615) 979-5778
Email: imaciasperez@cumberlandpharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Idiopathic Pulmonary Fibrosis
- Atezolizumab for Idiopathic Pulmonary Fibrosis — Los Angeles, California
- A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) — Quilmes, Buenos Aires
- A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis — Birmingham, Alabama
- LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) — Birmingham, Alabama
- Yoga Effect on Quality of Life Study Among Patients with Idiopathic Pulmonary Fibrosis — Seattle, Washington
- MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) — Camperdown, New South Wales
Explore by condition: All Idiopathic Pulmonary Fibrosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.